Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT04013542
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04007588
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1147
- Registration Number
- NCT04008030
- Locations
- 🇩🇪
Local Institution - 0117, Hamburg, Germany
🇩🇪Local Institution - 0008, Hannover, Germany
🇩🇪Local Institution - 0009, Heidelberg, Germany
IL13Ra2-CAR T Cells with or Without Nivolumab and Ipilimumab in Treating Patients with GBM
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT04003649
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 71
- Registration Number
- NCT03999749
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸NYU Langone Health, New York, New York, United States
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT03993379
- Locations
- 🇺🇸
Inova Dwight and March Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸Beacon Cancer Care, Coeur d'Alene, Idaho, United States
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03989362
- Locations
- 🇺🇸
University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Registration Number
- NCT03982121
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT03978611
- Locations
- 🇺🇸
Local Institution - 0002, Los Angeles, California, United States
🇧🇪Local Institution - 0018, Bruxelles, Brussels, Belgium
🇧🇪Local Institution - 0016, Brussels, Belgium
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 61
- Registration Number
- NCT03958383
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.